Maryland State Retirement & Pension System lowered its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 1.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,633 shares of the company’s stock after selling 528 shares during the period. Maryland State Retirement & Pension System’s holdings in Myriad Genetics were worth $758,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Myriad Genetics by 1.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 33,334 shares of the company’s stock worth $606,000 after purchasing an additional 509 shares during the period. Royal Bank of Canada increased its stake in shares of Myriad Genetics by 29.0% during the third quarter. Royal Bank of Canada now owns 2,339 shares of the company’s stock worth $44,000 after purchasing an additional 526 shares during the period. US Bancorp DE increased its stake in shares of Myriad Genetics by 14.6% during the first quarter. US Bancorp DE now owns 4,243 shares of the company’s stock worth $108,000 after purchasing an additional 541 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Myriad Genetics by 1.1% during the fourth quarter. State of Alaska Department of Revenue now owns 56,426 shares of the company’s stock worth $818,000 after purchasing an additional 600 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Myriad Genetics by 4.2% during the fourth quarter. Arizona State Retirement System now owns 22,753 shares of the company’s stock worth $330,000 after purchasing an additional 920 shares during the period. Institutional investors own 99.51% of the company’s stock.
Insider Buying and Selling at Myriad Genetics
In other Myriad Genetics news, Director Daniel K. Spiegelman sold 8,638 shares of the firm’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $23.01, for a total value of $198,760.38. Following the sale, the director now owns 40,493 shares of the company’s stock, valued at approximately $931,743.93. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.00% of the company’s stock.
Wall Street Analyst Weigh In
Myriad Genetics Price Performance
Shares of NASDAQ:MYGN opened at $22.53 on Friday. The business’s 50 day simple moving average is $21.70 and its 200 day simple moving average is $20.69. Myriad Genetics, Inc. has a 1 year low of $13.92 and a 1 year high of $28.18.
Myriad Genetics (NASDAQ:MYGN – Free Report) last issued its earnings results on Wednesday, May 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $181.20 million during the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative net margin of 21.05% and a negative return on equity of 7.42%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.14) EPS. On average, equities analysts predict that Myriad Genetics, Inc. will post -0.63 EPS for the current year.
Myriad Genetics Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Read More
- Five stocks we like better than Myriad Genetics
- Order From U.S. Army Fuels Surge In Enovix Stock
- The Bottom Is In For Mullen Automotive
- Could Meta Be Risking Another Sell Off With Its New “Threads”?
- 2 Must-Have Specialized ETFs for the Long-Term Investor
- Inspire Medical Up 15% After Breakout, Analysts Say It’s A Buy
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
